Sunitinib Malate in Treating Patients With Previously Untreated Metastatic Kidney Cancer

Summary

RATIONALE: Sunitinib malate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth or by blocking blood flow to the tumor. PURPOSE: This phase II trial is studying how well sunitinib malate it works in treating patients with previously untreated metastatic kidney cancer.

Timeline

Start

2010-08-18

Primary completion

2013-06-20

Completion

2017-02-01

Drugs

Indications